FutureTech II Acquisition Corp. Delays Quarterly Financial Report

FutureTech II Acquisition Corp. announced a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, due to needing more time to prepare and finalize financial statements. The report could not be filed within the prescribed period without unreasonable effort or expense.

FutureTech II Acquisition Corp. SEC 10-Q Report

FutureTech II Acquisition Corp. has released its SEC Form 10-Q report for Q2 2025, reporting net losses of $80,647 for the quarter and $370,320 for the six months. The company has extended its business combination period to August 18, 2025, and entered a merger agreement with Longevity Biomedical Inc. FutureTech II is also facing compliance challenges with Nasdaq listing standards and has issued zero interest convertible notes totaling $1,025,000. The company aims to complete the merger and regain compliance with listing standards.

FutureTech II Acquisition | 10-Q: FY2025 Q2 EPS: USD -0.04

FutureTech II Acquisition Corp. Delays Financial Report Due to Preparation Challenges

Future Tech II Acquisition Corp. has delayed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, citing the need for more time to prepare and finalize its financial statements. The company expects to report a net loss for the quarter due to a significant decrease in investment income compared to the previous year. The delay was deemed unavoidable without unreasonable effort or expense.

FutureTech II Acquisition Corp. Announces Date for Special Shareholder Meeting

FutureTech II Acquisition Corp. will hold a virtual special meeting of stockholders on August 14, 2025, to consider and vote on the Charter Amendment Proposal. This announcement was published via EDGAR by the U.S. Securities and Exchange Commission on July 17, 2025.